Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia's lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:Jason AdairChief Business Officer919.328.4350jason.adair@liquidia.com
Media: Patrick WallaceDirector, Corporate Communications919.328.4383patrick.wallace@liquidia.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Nvidia or Palantir: Morgan Stanley Selects the Superior AI Stock to Buy
A smart investor is always on the lookout for growth sectors, places where the economy is primed to boom and where consequent opportunities are riding high. Right now, few sectors are offering the strong growth potential of artificial intelligence (AI). Confident Investing Starts Here: In just a few short years, AI – and particularly generative and agentic AI – has become the 'shiny new thing' on the cutting edge of high-tech. The entry of AI is rapidly transforming the tech industry, and it is making inroads into numerous other areas. Data management, content creation, publishing – we've only begun to find out what AI can do, and we can only imagine what it will do. A report from UN Trade & Development points out that the world's AI market, which was estimated at $189 billion in 2023, will expand 25x by 2033 to reach $4.8 trillion. AI's growth will bring with it gains for companies across a wide spectrum of fields, including development, applications, hardware, infrastructure, and power generation. Such rapid growth is creating new opportunities for investors. The challenge won't be finding one – it'll be choosing the right one. That's where Morgan Stanley's analysts come in. They've zeroed in on two tech titans that have become synonymous with AI innovation: Nvidia (NASDAQ:NVDA) and Palantir (NASDAQ:PLTR). Both are riding the AI wave, but Morgan Stanley is making a clear call on which one stands out as the better buy right now. Let's take a closer look. Nvidi a Nvidia stands at the forefront of Wall Street's tech revolution. As a dominant force among the 'Magnificent 7' and boasting a $3.45 trillion market cap, it's not only the largest of the tech mega-cap – it's the biggest publicly traded company in the U.S. The AI boom, which took off in late 2022 with the debut of ChatGPT, put Nvidia in the spotlight. As the top supplier of high-performance GPUs, the company was well-positioned to meet the explosive demand for AI-capable chips – and that sent NVDA shares soaring 660% over the past three years. However, even a juggernaut like Nvidia isn't immune to shifting market dynamics. After an extraordinary run, the company's stock momentum has started to cool amid rising volatility this year. One key challenge stems from the lingering effects of President Trump's tariff policies. The chip industry is deeply intertwined with global supply chains, and Nvidia's exposure to East Asia has made it vulnerable to tariff risks. That may be easing now, as both China and the EU have entered into trade talks with the White House. Yet, Nvidia isn't standing still. The company continues to push the boundaries of innovation, doubling down on emerging technologies to maintain its leadership in the AI race. This past May, Nvidia unveiled the world's largest dedicated quantum computing research supercomputer, the ABCI-Q, hosted at the Global Research and Development Center for Business by Quantum-AI Technology (G-QuAT). The new system is already integrated with Nvidia's open-source hybrid computing platform CUDA-Q. A second new development was made public last week. Nvidia announced that its Blackwell architecture, designed to power the latest AI platforms, showed superior performance on the latest rounds of the MLPerf Training, a key benchmark used to rate the capabilities of new AI systems. In Nvidia's last earnings report, covering fiscal 1Q26, company CEO Jensen Huang noted that the company's breakthrough Blackwell products are in full production and went on to outline the potential for AI to continue supporting strong results: 'Global demand for NVIDIA's AI infrastructure is incredibly strong. AI inference token generation has surged tenfold in just one year, and as AI agents become mainstream, the demand for AI computing will accelerate.' Turning to the company's financial results for the quarter, we find that Nvidia's revenue came in at $44.1 billion, up 69% year-over-year and $810 million better than had been expected. The company's non-GAAP EPS figure, at 81 cents, was 6 cents per share above the forecasts. Data center revenue, at $39.1 billion, was the main revenue driver and was up 73% year-over-year. Nvidia's gross margin for the quarter was reported at approximately 61%. For 5-star analyst Joseph Moore, the key point for investors to remember about Nvidia is that the future looks good. The Morgan Stanley analyst writes in his note on this chip maker: 'Racks get better from here. China is entirely derisked, at least for direct shipments, and we are optimistic that there will be some path to monetize at least a portion of that demand. Gross margins have bottomed and are improving to the mid 70s, sustainably. And every customer commentary confirms that customers waiting for these new technologies have left demand on the table. So our confidence in durable demand drives is quite high. We think that our numbers are conservative given the variables at play, and we see a high probability of continued upward revisions.' Moore's comments support his Overweight (i.e., Buy) rating on NVDA stock, while his $170 price target points toward a one-year upside potential of 20%. (To watch Moore's track record, click here) Overall, Nvidia has earned a Strong Buy consensus rating from the Street's analysts, based on 40 reviews that include 35 Buys, 4 Holds, and 1Sell. The stock is priced at $141.72 and its $172.36 average price target implies a ~22% upside in the next 12 months. (See NVDA stock forecast) Palantir Technologies Palantir is another standout in the AI space. Founded in 2003 by venture capitalist Peter Thiel, the company has built a strong reputation as a leader in data analytics and software solutions. Like Nvidia, Palantir has leveraged its unique capabilities to ride the wave of the AI boom, and the results have been striking. Over the past three years, its stock has skyrocketed 1,291%, including a 69% gain year-to-date. These gains haven't come by chance. Palantir stock's growth is rooted in the strength of its data management and analysis tools, which are used by businesses, non-profits, and government agencies alike. At the center of its offerings is the AI Platform (AIP), a solution that blends advanced AI capabilities with human-driven decision-making. One of its key strengths lies in its accessibility – users can interact with the platform using natural language, without needing coding expertise. AIP also supports multilingual inputs and translation frameworks, making it easier for users around the world to engage with its tools. Palantir can currently boast more than 760 customers, from both the public and private sectors. The company's AI-powered data platforms are popular with big businesses, and Palantir can count such names as Stellantis and BP among its users, as well as the US Department of Defense. In May, Palantir received a $795 million contract modification to its Maven Smart System agreement with the Army, extending support through 2029. The company is also among the short‑listed firms – alongside SpaceX, Lockheed Martin – and others, being considered for President Trump's $175 billion Golden Dome missile defense program. On the financial side, Palantir has been singularly successful at generating strong revenues and earnings. In 1Q25, the last period reported, the company had a top line of $883.9 million, representing 39% year-over-year growth and beating the forecast by $21.72 million. At the bottom line, Palantir's EPS came to 13 cents in non-GAAP terms, matching analyst expectations. The company proved successful at closing large deals during the quarter, including 31 deals worth at least $10 million. Despite this strength, some caution is warranted. Morgan Stanley's Sanjit Singh remains confident in Palantir's fundamentals but cautions that the valuation may be stretched after such a strong run. 'Palantir continues to prove out that it is one of the clear AI winners in software which has translated to accelerating top-line growth of 30%+ and a rule of 40 score (revenue growth + operating margin) of 83%. While this represents elite level performance in software, the current valuation of ~95x CY27 FCF makes underwriting a return on Palantir shares extremely challenging. As a result, we remain EW and await a better entry point before getting more bullish,' Singh noted. Singh's Equal Weight (i.e., Hold) rating comes with a $98 price target, implying a potential 25% drop from current levels. It's safe to say that his ideal entry point lies somewhere south of that. (To view Singh's track record, click here) Morgan Stanley's view aligns with the broader Street consensus. Palantir holds a Hold rating overall, based on 18 recent analyst recommendations: 3 Buys, 11 Holds, and 4 Sells. The stock is currently trading at $127.72, while the average price target stands at $100.13, implying a potential ~22% downside over the coming year. (See PLTR stock forecast) With the facts laid out, the Morgan Stanley analysts come to a clear conclusion: Both of these AI stocks are solid performers, but Nvidia is the superior choice to buy right now. To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
an hour ago
- Yahoo
High Growth Tech Stocks To Watch In Europe June 2025
As the European markets experience a boost, with the STOXX Europe 600 Index climbing by 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are increasingly focusing on high-growth sectors such as technology. In this environment, identifying promising tech stocks involves looking for companies that can leverage favorable economic conditions and technological advancements to drive substantial growth. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 226 stocks from our European High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Growth Rating: ★★★★★★ Overview: argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across several countries including the United States, Japan, China, and the Netherlands, with a market cap of €31.52 billion. Operations: argenx focuses on developing therapies for autoimmune diseases, generating revenue primarily from its biotechnology segment, which reported $2.64 billion. The company's operations span multiple countries, including the United States, Japan, China, and the Netherlands. argenx SE has demonstrated remarkable growth with a surge in revenue to $807.37 million, doubling from the previous year's $412.51 million, alongside transitioning from a net loss to a substantial net income of $169.47 million. This financial turnaround is underscored by robust R&D commitments, crucial for sustaining innovation and competitiveness in the biotech landscape. The firm's recent CHMP nod for VYVGART® in CIDP treatment further highlights its strategic focus on expanding therapeutic applications, promising continued relevance and impact within the healthcare sector. Click here to discover the nuances of argenx with our detailed analytical health report. Understand argenx's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Believe S.A. is a company that offers digital music services to independent labels and local artists across various regions including France, Germany, the rest of Europe, the Americas, Asia, Oceania, and the Pacific with a market cap of approximately €1.72 billion. Operations: The company's revenue primarily comes from Premium Solutions, generating €924.24 million, while Automated Solutions contribute €64.59 million. Believe, a European tech entity, is navigating its path towards profitability with expected earnings growth of 96.9% annually. Despite current unprofitability, its revenue growth outpaces the French market's average at 13.4% per year compared to 5%. This growth trajectory is supported by strategic moves such as the proposed acquisition by TCMI Inc., EQT X, and Denis Ladegaillerie for a €57.9 million stake, enhancing financial stability and market presence. Moreover, Believe's commitment to R&D aligns with industry demands for continuous innovation, ensuring it remains competitive in the dynamic tech landscape. Get an in-depth perspective on Believe's performance by reading our health report here. Examine Believe's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Comet Holding AG, along with its subsidiaries, delivers X-ray and radio frequency (RF) power technology solutions globally across Europe, North America, and Asia, with a market capitalization of CHF1.79 billion. Operations: The company generates revenue through three main segments: X-Ray Systems (CHF115.89 million), Industrial X-Ray Modules (CHF94.57 million), and Plasma Control Technologies (CHF247.39 million). Comet Holding AG, a Swiss tech firm, is making notable strides with an earnings growth of 37.3% annually, significantly outpacing the local market's average of 10.7%. This robust performance is further underscored by its revenue increase of 12.2% per year, which also surpasses the Swiss market growth rate of 4.2%. Notably, Comet's commitment to innovation is evident in its R&D spending, crucial for maintaining technological leadership in a competitive sector. Recent corporate actions include electing Benjamin Loh as Chairman and approving a dividend increase to CHF 1.50 per share, signaling strong governance and shareholder confidence amidst a promising financial trajectory marked by first-quarter sales surging by 37.5% year-over-year to CHF 111.2 million. Take a closer look at Comet Holding's potential here in our health report. Assess Comet Holding's past performance with our detailed historical performance reports. Dive into all 226 of the European High Growth Tech and AI Stocks we have identified here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTBR:ARGX ENXTPA:BLV and SWX:COTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Business Upturn
2 hours ago
- Business Upturn
Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval
Glenmark Pharmaceuticals has announced the launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). The drug will be marketed under the brand name BRUKINSA®, developed by BeiGene (now BeOne Medicines), a global oncology company. This marks the introduction of the first Bruton's tyrosine kinase (BTK) inhibitor in India approved for the treatment of five B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). BRUKINSA is approved in over 70 countries, backed by data from clinical studies such as ALPINE, ASPEN, and SEQUOIA. These trials have demonstrated consistent clinical outcomes across various B-cell cancers. The availability of BRUKINSA in India comes at a time when blood cancers continue to impact a large number of individuals. Estimates suggest that someone is diagnosed with blood cancer every five minutes in India, with annual deaths from the disease numbering around 70,000. The treatment has shown high response rates and the ability to maintain disease control in patients with different types of B-cell malignancies. It also offers dosing flexibility, allowing for once or twice-daily administration. In the ALPINE study, BRUKINSA was compared with ibrutinib in relapsed or refractory CLL and showed a lower rate of serious cardiac events and fewer treatment discontinuations due to cardiac-related issues. With its recent regulatory approval, BRUKINSA will now be available to patients in India who are affected by challenging hematological cancers. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
